CARLSMED, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
CARL$14.71-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental Disclosure of Noncash Investing and Financing Activities: | ||
| Conversion of convertible preferred stock upon initial public offering | $— | $108,729 |
| Reclassification of warrants from liability classified to equity classified | $— | $760 |
| Right-of-use assets obtained in exchange for lease liabilities | $5,027 | $593 |
| Property and equipment obtained in exchange for lease liability | $270 | $— |
| Vesting of early exercised common stock options | $70 | $31 |
| Purchases of property and equipment in accounts payable and accrued liabilities | $385 | $— |
| Capitalized internal use software included in accounts payable and accrued liabilities | $505 | $— |
| Cash, Cash Equivalents, and Restricted Cash Information: | ||
| Cash and cash equivalents, beginning of period | $85,793 | $40,125 |
| Restricted cash, beginning of period | 100 | 100 |
| Cash, cash equivalents, and restricted cash, beginning of period | 85,893 | 40,225 |
| Cash and cash equivalents, end of period | 35,945 | 115,373 |
| Restricted cash, end of period | 100 | 100 |
| Cash, cash equivalents, and restricted cash, end of period | $36,045 | $115,473 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.